Accelerating precision medicine of cancer with SomaScan® proteomics
Accelerating precision medicine of cancer
with SomaScan proteomics
Proteomics has emerged as the next frontier in precision medicine, and several innovative proteomics platforms have been developed to drive biomarker discovery. We [at Beth Israel Deaconess Medical Center] are using the currently most comprehensive proteomics technology — the SomaScan Platform, which measures 7,000 proteins — to discover and independently validate diagnostic, predictive, and prognostic biomarkers for various cancers.
Efforts are especially focused on non-invasive biomarkers in serum, plasma, urine, and exosomes for a broad range of clinically highly relevant and challenging indications. Protein biomarker efforts for early detection of liver cancer and for predicting response to immunotherapy in metastatic melanoma will also be presented.
Learn about:
- Plasma protein biomarkers for predicting response to immunotherapy in metastatic melanoma
- Serum protein biomarkers for differential diagnosis of oral squamous cell carcinoma
- Plasma protein biomarkers for pancreatic cancer
- Exosome protein biomarkers for pancreatic cancer
- Urine protein biomarkers for pancreatic cancer and triple negative breast cancer
- Pre-diagnostic plasma protein biomarkers for early detection of hepatocellular cancer
Towia Libermann, PhD
Towia Libermann, PhD, is Associate Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center. He is also the Director of the Beth Israel Deaconess Medical Center Genomics, Proteomics, Bioinformatics and Systems Biology Center and of the Dana Farber/Harvard Cancer Center Cancer Proteomics Core.
Accelerating precision medicine of cancer with SomaScan proteomics
A presentation by Towia Libermann, PhD
More webinars
WebinarBoutique Webinar Aptamers with protein-like side chains as a versatile tool for high-content proteomics
Proteins, encoded in 20,000 genes in humans, do much of the work in biology. Measuring proteins, which change in response to various perturbations and represent targets for almost all drugs, offers insights about the health status of an organism. Since proteins operate in complex networks rather than in isolation, measuring multiple proteins simultaneously offers richer insights compared to single protein measurements.
WebinarUsing Proteomics To Advance Understanding of Alzheimer’s Disease
Limited understanding due to its complex pathophysiology and lack of definitive biomarkers currently constrains the diagnosis and treatment of Alzheimer’s disease (AD). But new research is uncovering dynamic brain changes during Alzheimer’s progression, offering potential therapeutic targets. This webinar explores how proteomics and systems biology can be integrated to elucidate AD pathology.
WebinarPredictive modeling and reliable biomarker discovery in clinical omics studies
High-content omic technologies coupled machine learning methods have transformed the biomarker discovery process. However, the translation of computational results into scalable clinical biomarkers remains challenging. A rate-limiting step is the rigorous selection of reliable biomarker candidates among a host of biological features. Drawing examples from real-world clinical omics studies, I will introduce Stabl, a general machine learning framework that identifies a sparse, reliable set of biomarkers by integrating noise injection and a data-driven signal-to-noise threshold into multivariable predictive modeling.